<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551807</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00214688</org_study_id>
    <nct_id>NCT04551807</nct_id>
  </id_info>
  <brief_title>Natural Versus Programmed Frozen Embryo Transfer (NatPro)</brief_title>
  <acronym>NatPro</acronym>
  <official_title>Multi-center, Parallel-group, Randomized Controlled Trial of Modified Natural Versus Programmed Cycles for Frozen Embryo Transfers and Their Association With Preeclampsia and Live Births</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHSPH Center for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JHSPH Center for Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NatPro is a two-arm, parallel-group, multi-center, randomized trial in which women undergoing&#xD;
      frozen embryo transfer (FET) will be randomized to receive either a modified natural cycle&#xD;
      (corpus luteum present) or a programmed cycle (corpus luteum absent).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NatPro is a two-arm, parallel-group, multi-center, randomized trial in which women undergoing&#xD;
      FET will be randomized to receive either a modified natural cycle (corpus luteum present) or&#xD;
      a programmed cycle (corpus luteum absent). The study will implement a stratified&#xD;
      randomization design to balance the use of pre-implantation genetic testing (PGT) across the&#xD;
      two treatment arms. Each participant will have up to 3 FET cycles until live birth occurs, or&#xD;
      the participant has no embryos available for transfer. Primary endpoints will be the&#xD;
      proportion of women experiencing preeclampsia comparing modified natural to programmed FET&#xD;
      among women with viable pregnancy (defined as pregnancy lasting at least 20 weeks) and the&#xD;
      cumulative proportion of women having live births in the two arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preeclampsia</measure>
    <time_frame>During pregnancy through the post-partum period, according to ACOG guidelines (typically between 20 weeks gestation and 6 weeks post-delivery)</time_frame>
    <description>Frequency of preeclampsia, as defined by American College of Obstetricians and Gynecologists (ACOG) guidelines for hypertensive disorders in pregnancy (Obstetrics &amp; Gynecology 2020;135:e237-e260)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">788</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>Modified natural cycle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>corpus luteum present</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Programmed cycle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>corpus luteum absent</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Modified natural cycle</intervention_name>
    <description>This treatment protocol is defined as a modified natural cycle as the participant will be instructed to (1) administer human chorionic gonadotropin (hCG) to assist with timing of the embryo transfer and (2) supplement the luteal phase with a low dose of progesterone.</description>
    <arm_group_label>Modified natural cycle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Programmed cycle</intervention_name>
    <description>This protocol is designated as programmed because the endometrial development occurs only in association with administration of estradiol and progesterone. No ovulation occurs due to suppression of follicle development by the estradiol and the timing of the transfer is based on the number of days elapsed following initiation of exogenous progesterone.</description>
    <arm_group_label>Programmed cycle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        To be eligible, subjects must meet all these criteria:&#xD;
&#xD;
          -  Age 18-39 years at the time that embryos were created if no pre-implantation genetic&#xD;
             testing (PGT) testing was performed. If PGT testing was performed and indicates that&#xD;
             an embryo is euploid, the patient can be included if she was age 18-41 years at the&#xD;
             time that the embryo was created.&#xD;
&#xD;
          -  Age 18-41 years at the time of randomization&#xD;
&#xD;
          -  Normal uterine cavity as assessed by saline infusion sonohysterogram,&#xD;
             hysterosalpingogram, or hysteroscopy within one year of the enrollment visit, and&#xD;
             repeated at the discretion of the investigator&#xD;
&#xD;
          -  Regular menstrual cycle length (approximately 24-35 days) indicative of ovulatory&#xD;
             cycles.&#xD;
&#xD;
          -  Willing to undergo elective single embryo transfer&#xD;
&#xD;
          -  Body Mass Index&lt;=40&#xD;
&#xD;
          -  If Body Mass Index is over 30 or individual has other risk factors for diabetes,&#xD;
             normal hemoglobin A1c&#xD;
&#xD;
          -  Prior to enrollment, participant will have at least one vitrified blastocyst with&#xD;
             euploid result by pre-implantation genetic testing (PGT-A) or at least one vitrified&#xD;
             blastocyst of fair or better morphologic quality if no PGT-A results are available.&#xD;
&#xD;
          -  Willingness to be randomized to either a modified natural or programmed cycle, with a&#xD;
             willingness to administer daily intramuscular progesterone in oil if assigned to the&#xD;
             programmed cycle.&#xD;
&#xD;
          -  Normal thyroid stimulating hormone (TSH) , according to local laboratory standards,&#xD;
             within one year of study enrollment and repeated at the discretion of the&#xD;
             investigator. Use of thyroid medication is permitted.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        To be eligible, subjects must not meet any one of these criteria:&#xD;
&#xD;
          -  Medical contraindication to pregnancy&#xD;
&#xD;
          -  Embryos created using donor oocytes&#xD;
&#xD;
          -  Embryo donation&#xD;
&#xD;
          -  Gestational carrier&#xD;
&#xD;
          -  Reciprocal In vitro fertilization (IVF) (one female partner carrying pregnancy, other&#xD;
             female partner as source of eggs)&#xD;
&#xD;
          -  Embryos created from frozen oocytes&#xD;
&#xD;
          -  Recurrent implantation failure defined as no clinical pregnancy with â‰¥2 prior&#xD;
             consecutive embryo transfers unless patient also had successful live birth with IVF&#xD;
&#xD;
          -  Anti-phospholipid antibody syndrome or rheumatologic disease requiring chronic&#xD;
             systemic medications&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  History of &gt;1 pregnancy loss in the second or third trimester&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Untreated hydrosalpinx (i.e., hydrosalpinx in situ which has not been ligated or&#xD;
             removed)&#xD;
&#xD;
          -  Physician recommendation to perform the embryo transfer outside of the timing&#xD;
             specified by the protocol&#xD;
&#xD;
          -  Contraindication to any medication which must be used in preparation for the frozen&#xD;
             embryo transfer (i.e., estradiol, progesterone, Human chorionic gonadotropin (hCG)).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women attempting to get pregnant using frozen embryos</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerie Baker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Segars, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Shade, JD</last_name>
    <phone>410-955-8175</phone>
    <email>dshade@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94087</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alma Gonzalez</last_name>
      <phone>408-688-9892</phone>
      <email>agonlez@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Ruth Lathi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindy Christianson, MD</last_name>
      <phone>410-583-2761</phone>
      <email>mchris21@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bhuchitra Singh</last_name>
      <phone>4106142000</phone>
      <email>bsingh10@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mindy Christianson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shady Grove Fertility</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Team</last_name>
      <phone>301-545-1423</phone>
      <email>sgfclinicalresearchteam@sgfertility.com</email>
    </contact>
    <contact_backup>
      <last_name>Tasha Newsome</last_name>
      <phone>301-545-1289</phone>
      <email>Tasha.Newsome@sgfertility.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kate Devine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynda Kochman</last_name>
      <phone>585-275-0250</phone>
      <email>lynda_kochman@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Wendy Vitek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Andrews</last_name>
      <phone>704-953-4832</phone>
      <email>mary.andrews@atriumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Hoelscher</last_name>
      <email>gretchen.hoelscher@atriumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rebecca Usadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Starkey-Scruggs</last_name>
      <phone>405-271-9204</phone>
      <email>Michelle-StarkeyScruggs@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Karl Hansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CARE Fertility</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aracely Casillas</last_name>
      <phone>817-540-1157</phone>
      <email>aracelyc@embryo.net</email>
    </contact>
    <investigator>
      <last_name>Kevin Doody, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>frozen embryo transfer</keyword>
  <keyword>infertility</keyword>
  <keyword>in vitro fertilization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

